Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048087
Status:
WITHDRAWN
Last Update Posted:
2012-07-31
First Post:
2002-10-24
Brief Title:
IressaDocetaxel in Non-Small-Cell Lung Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Phase II Study of ZD1839 Iressa Epidermal Growth Factor Receptor EGFR Tyrosine Kinase Inhibitor in Combination With Docetaxel in Patients With Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer
Status:
WITHDRAWN
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients will receive 250 mg Iressa by mouth daily each day while on this study Patients will also receive docetaxel 30 mgm2 by by vein IV on day 1 weekly for the first 3 weeks of each course of therapy A course of therapy is 4 weeks Patients will not receive docetaxel during week 4 A maximum of 8 full cycles of docetaxel plus Iressa are planned Patients may continue on daily Iressa until progressive disease andor unacceptable toxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None